RxDoctor Payments Data

Jay Stack, MD

Nephrology · Morristown, NJNPI 1245325026

Payments from drug & device makers

$3,615in general payments, 2019–2025

Across 149 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$624
  • Otsuka America Pharmaceutical, Inc.$542
  • Travere Therapeutics, Inc.$243
  • OPKO Pharmaceuticals, LLC$182
  • GSK$177
  • plus $739 from 13 others

What the payments were for

  • Consulting fees$44012%
  • Food & beverage$2,95282%
  • Education$2226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,615 in reported general payments places this provider in the 75th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$215,377
Medicare patients
241
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$98,539
VelphoroSucroferric Oxyhydroxide12$19,080
LokelmaSodium Zirconium Cyclosilicate13$16,073
Sevelamer Carbonate41$9,080
Calcium Acetate17$4,399
Potassium Citrate ErPotassium Citrate27$4,209
Cinacalcet Hcl26$1,925
Midodrine Hcl13$1,814
Amlodipine Besylate115$1,200
Doxazosin Mesylate36$1,162
Tamsulosin Hcl42$952
Torsemide35$900
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$708
Allopurinol55$651
Simvastatin56$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,108$114,61192 claims
Fresenius USA Marketing, Inc.Velphoro$22$19,08012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →